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1. Introduction 
From the nephrological point of view, the last couple of years have brought some major 
advances both in our understanding of ANCA positive vasculitis pathogenesis mechanisms 
and in treatment options. Recent discoveries of completely new antigens such as LAMP-2 
meant a huge step forward, and the fact that this antigen is homologous to proteins of 
bacterial fimbria caused a shift in the focus regarding underlying pathomechanisms of 
ANCA vasculitis towards bacterial infections, mainly with Klebsiella or Escherichia species, 
playing a major role in triggering the disease. So nephrology has seen real progress in our 
understanding of glomerulonephritis disease mechanisms – not only regarding primary 
membranous glomerulonephritis (with the recent identification of the phospholipase A2 
receptor being the underlying antigen) but also regarding secondary pauci-immune 
glomerulonephritis due to ANCA positive vasculitis. 
At the same time, some important studies were successfully conducted. Especially the 
results of the RAVE and IMPROVE studies, will have an impact on nephrologists´ 
approaches to the treatment of patients suffering from this type of vasculitis. 
The following chapter will focus on the new developments and briefly outline our already 
well established knowledge about ANCA positive vasculitis from a nephrological point of 
view. 
2. Pathogenesis of ANCA positive vasculitis 
There has been a long debate about the actual role of ANCA autoantibodies as causative 
agents of small vessel vasculitis . Although the correlation of ANCA titres with disease 
activity is not very strong 12, the fact that drug induced ANCA formation in patients treated 
with propylthiouracil, hydralazine or penicillamine can lead to exactly the same clinical 
picture of pauci-immune glomerulonephritis as “idiopathic” ANCA disease seams to 
indicate a causative role of the antibodies3. A well documented case report of a neonate with 
glomerulonephritis (GN) and pulmonary vasculitis due to Anti-MPO-antibodies that had 
passed the placental barrier from the maternal circulation4 points in the same direction. The 
ability of these antibodies to cause GN when administered to mice intravenously has also 
been demonstrated5.  
The course of events leading to the inflammatory destruction of endothelial cells starts with 
activated neutrophils, which represents the flu-like initial phase of the disease. Cytokine 
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activated neutrophils present antigens at their surface which attract IgG ANCA´ s binding to 
them, forming local immuncomplexes. Recent results show an essential involvement of the 
alternative complement pathway in these complexes – C3 and C5 rather than C4 are the 
main complement fragments involved. C5 knock out mice will not develop Anti-MPO 
antibody induced vasculitis6, depletion of neutrophils also prevents the disease despite 
ANCA´s being administered, as demonstrated in an animal model7. T cells play a role in the 
pathogenesis, and so do B cells -indicated by the fact that anti-B cell agents such as 
rituximab are highly effective in therapy. Th17 cells are the major effector cells, while Th1, 
Th1 and regulatory T cells are also involved. Activated B cells produce the ANCA 
antibodies, and their number correlated with the disease activity. However, the actual role 
of B cells still needs to be elucidated.  
While 70% of ANCA positive patients will show renal manifestations, there are about 10% 
of patients with the same clinical picture of pauci-immune GN who are ANCA negative. 
Conceivably other, as yet unknown antibodies might be involved in this patient subgroup. 
Similarly, the two classical antigens of proteinase 3 (c-ANCA´s) and myeloperoxidase (p-
ANCA´s) are not the only ones, the lysosomal membrane protein lamp-2 which has a 
homologue protein in renal glomerular endothelial cells, is another important target of 
ANCA´s8. In fact this ANCA subtype is present in almost all patients with pauci-immune 
focal necrotizing glomerulonephritis. Most interestingly, lamp-2 is highly similar to certain 
bacterial fimbria proteins, as recently reported by Kain et al in Nature Medicine in 20089. 
Some peptides of proteinase3 resemble epitopes of staphylococcus aureus antigens. Bacterial 
infections mainly with Klebsiella and Escherichia coli species may therefore trigger systemic 
ANCA associated vasculitis via a cross-reactivity mechanism. 
3. The beginning of the LAMP story 
In 1988, isolation and characterization of two human lysosomal membrane glycoproteins 
was reported by Carlsson et al. and the terms h-lamp-1 and h-lamp-2 introduced (“LAMP” 
being the acronym for lysosome associated membrane protein). The two major lysosomal 
membrane glycoproteins were described as major sialoglycoproteins carrying 
polylactosaminoglycan 10, with apparent molecular weights of 39.5 and 41.5 kDa, 
respectively. They were purified from chronic myelogenous leukemia cells. Already at this 
early stage it was noted that the apparent molecular weights differed between cell lines and 
that “this probably represents differences in the amount of polylactosaminoglycan 
expressed by each cell line”. The first one of the glycoproteins was found to be very 
homologous to that of a mouse counterpart, m-lamp-1, it was therefore named human lamp-
1 (h-lamp-1), while the other glycoprotein was called human lamp-2 (h-lamp-2). After 
cloning both proteins in the same year11 , it became clear that major portions of both h-lamp-
1 and h-lamp-2 reside on the luminal side of the lysosome and are heavily glycosylated by 
N-glycans: h-lamp-1 and h-lamp-2 were found to contain 19 and 16 potential N-
glycosylation sites, respectively. Strong homology was noted and a common ancestor gene 
suggested. Diversion had to have happened at an early evolutionary stage however, since 
human lamp-1 has more similarity to lamp-1 from other species than to human lamp-2. Both 
LAMP`s are structural proteins without enzymatic activity. By means of in situ 
hybridization, the gene for human lamp-2 was localized to chromosome 12p133 and the h-
lamp-1 gene to chromosome 13q3412 . The authors argued that the fact of two genes on 
different chromosomes indicates that lamp-1 and lamp-2 diverged early in evolution and 
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probably have distinct functions which emerged as soon as eukaryotic cells acquired 
lysosomes as subcellular compartments. When mouse LAMP-2 had been cloned 13 it was 
found that mouse LAMP-2 and human LAMP-2 form one homology class (LAMP-2) that is 
separated from the LAMP-1 class of proteins. The localization of the 
polylactosaminoglycans 14 in the two lysosome membrane glycoproteins was analyzed, and 
in 1990 rat LAMP-2 was purified15  and found to be present in all rat tissues examined, but 
at consistently lower concentrations than LAMP-1. The authors reported that their apparent 
molecular weights differed among the tissues, suggesting different glycosylation patterns. 
Later a soluble LAMP-2 was detected in rat liver16. When the exon structure of both protein 
classes was analyzed17, it turned out that each of the nine exons encodes almost identical 
portions of the proteins. Since the amino acid sequence of human lamp-1 is more 
homologous to lamp-1 of other species than it is to human lamp-2, the two genes were most 
likely produced by duplication of a primordial gene, which took place early in evolution. 
The old age, in evolutionary terms, of the LAMP-2 gene, is in fact not trivial but will shed 
some light on the pathogenetic role of this protein as the LAMP story unfolds. Homology 
with another protein outside the LAMP-2 class was already reported in 199318 , when 
glycoprotein II (GpII), a heterogenous glycoprotein isolated from the membranes of 
secretory chromaffin granules in the adrenal medulla was found to show a homology of 
greater than 70% of the sequence with LAMP-1 and –2. It became clear19, that the LAMP-2 
gene is in fact preserved from birds to mammals and all diversity due to alternative splicing 
from a single gene. In the following years a number of papers dealt with structural 
properties of the protein and its processing within the cell. So it was reported, that 20 clusters 
of O-glycans protect LAMP-2 from intralumenal lysosomal proteases - after removal of the 
asparagine-linked glycans from fully folded lysosomal membrane proteins by 
endoglycosidase H in cell culture, both LAMP-1 and LAMP-2 are rapidly degraded21. 
Tissue-specific expression of three different LAMP-2 variants due to alternative splicing was 
reported22 in chicken. In cell culture it was found, that lamp-2, similar to lysosomal acid 
phosphatase (LAP), shuttles23 in the endocytic membrane transport system of rat 
hepatocytes between lysosomes and the plasma membrane. After leaving the rough 
endoplasmic reticulum, newly synthesized lamp-2 is transported24 to the trans-Golgi and 
then transferred to at least three compartments - the cell surface, cell peripheral early 
endosomes and perinuclear late endosomes, before it is finally delivered to the lysosomes. 
The extent of polylactosamine glycosylation of MDCK LAMP-2 is determined by its Golgi 
residence time25. Where the molecule will travel is governed by the COOH-terminal residue 
of its cytosolic tail26. Its plasma membrane variant was discussed as a possible tumour 
antigen; it was speculated, that LAMP-1 and -2 like several other glycoproteins27 might be 
important in colon carcinoma adhesion and metastasis by functioning as its endogenous 
ligands – in fact there is evidence28 suggesting an increase in their cell-surface expression in 
tumor cells, with some data indicating that the adhesion of some cancer cells to the 
extracellular matrix is partly mediated by interactions between LAMP´s and E-selectin and 
between Lamps and galectins (endogenous-galactoside-binding lectins). However, its 
physiological role and main pathophysiological importance remained unclear, until the next 
major discovery was made. 
4. LAMP-2 as an additional autoantigenic ANCA target 
While the association between the clinical picture of pauci-immune, necrotizing and crescentic 
glomerulonephritis (NCGN) with circulating antineutrophil cytoplasmic autoantibodies 
(ANCA) had been known for some time, only two of the actual targets had been identified 
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until 1995: proteinase 3 (mainly associated with c-ANCA) and myeloperoxidase (mainly 
associated with p-ANCA). Then the group of Renate Kain et al. reported LAMP-2 to be 
another antigen targeted by ANCA, and they also found the link to the underlying disease 
mechanism when they identified gp130, a glycoprotein in the endothelial membranes of renal 
glomeruli, to be highly homologous to LAMP-229. The same group later showed, that almost 
all patients with pauci-immune focal necrotizing glomerulonephritis have ANCA´s against 
LAMP-2, so that their prevalence is almost twice that of Anti-proteinase 3 and 
myeloperoxidase ANCA´s. They also demonstrated30 the pathophysiological significance of 
these antibodies, since Anti-LAMP-2 ANCA´s injected into rats caused the same histological 
picture of pauci-immune focal necrotizing glomerulonephritis. In vitro, these antibodies cause 
apoptosis in microvascular endothelium. When studying the epitope, to which the ANCA´s 
commonly bound, it turned out that this part of the LAMP-2 protein had a 100% homology 
with to the bacterial adhesin FimH, a protein present in bacterial fimbria. The terminology of 
p- and c-ANCA refers to the distinct staining patterns due to the intracellular localization of 
the respective antigens. LAMP-2 is also localized in specific lysosomal fractions – together with 
Lamp-1 it is present in the specific-granule-enriched fraction and in the light-membrane 
fraction31, but not in the azurophil granules. These further studies, fuelled by the increased 
interest in the LAMP´s as intracellular antigens, began to clarify their physiological role: 
Separation of secretory vesicles from plasma membranes disclosed that the light-membrane 
LAMP´s are present primarily in the secretory-vesicle-enriched fraction, and during 
phagocytosis both Lamp-1 and Lamp-2 become markedly concentrated around the ingested 
particle. Both appear on the cell surface when the secretory organelles are mobilized. This fact 
sparks the ongoing interest in Lamp-2 as a tumour marker, because - other than in the 
lysosomal membrane - Lamp-2 proteins are expressed at the plasma membrane of cells in a 
differentiation dependent and activation dependent manner32. Murine Lamp-2c expression is 
pronounced in mesenchyme early in development, in limb connective tissue, and in lung 
parenchyma, whereas m-Lamp-2a is prevalent in the liver, the pancreas, and in differentiating 
kidney epithelium, and becomes increasingly prominent in the epithelial lining of the digestive 
and the respiratory tract during development. Their expression pattern becomes more tissue 
and cell type specific as differentiation progresses. In adults, tumour cells undergoing 
dedifferentiation again have detectable amounts of LAMP-2 at their cell surface, where they 
might play a role in cell adhesion, metastasis or tumour progression, as a study about LAMP-1 
in pancreatic carcinoma33 suggests. Since morphogenesis often requires apoptotic removal of 
cells, an important role of phagolysosome activities and lysosomal proteins in these processes 
is evident. 
5. Learning from rare genetic deficiencies: Danon´s disease and LAMP-2 
The first time, when a rare genetic condition provided insight into the physiological role of 
LAMP-2, was when control platelets and those from an individual with Hermansky-
Pudlak34 syndrome were compared35 regarding the presence of LAMP-2 expression: It 
turned out that LAMP-2, like CD63, is normally present not only in lysosomes but also in 
dense granules of platelets. Apart from oculocutaneous albinism, this autosomal recessive 
condition is characterised by platelet dense granule deficiency, prolonged bleeding time, a 
storage pool deficiency of platelets and lysosomal accumulation of ceroid lipofuscin. A 
major breakthrough in the understanding of the physiological role of LAMP-2 came with 
studies of knock-out lab animals and the discovery of Nishino, DiMauro et al. that the rare 
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condition of Danon´s36 disease is due to LAMP-2 deficiency. It became evident, that a 
deficiency of this protein mainly impairs autophagy, i.e. the removal of aged cell material, 
lysosome biogenesis and cholesterol homoeostasis37 – being a structural protein it has no 
enzymatic activity of its own, but a deficiency leads to partial mistargeting of a subset of 
lysosomal enzymes38. Lysosomal cholesterol transport39, the ability of lysosomes to migrate 
by means of dynein-mediated transport and the fusion with autophagosomes and 
phagosomes depend on the LAMPs40. Therefore phagocytosis is also affected, and 
pathogenic Neisseria have been found to excrete a protease which selectively cleaves 
LAMP-141. In the unicellular eukaryote Paramecium LAMP-2 was found to be required for 
phagosome maturation42. Since antigen presenting B-cells rely on normal lysosomal 
function, MHC class II antigen presentation to CD4 T-cells and the balance between 
endogenous and exogenous antigen presentation is impaired43 in LAMP-2 deficiency. 
The condition was first characterized by Moris J. Danon and Shin J.Oh in two patients as a 
'lysosomal glycogen storage disease with normal acid maltase' in 198144– the clinical picture 
involves hypertrophic cardiomyopathy (often associated with Wolff-Parkinson-White 
syndrome), myopathy and variable mental retardation. It was initially thought to be mainly 
X-linked, but as DiMauro et al. recall in their review45, in 1993 they wrote that an 
“autosomal dominant inheritance cannot be ruled out”. In the meantime more than 20 
autosomal mutations of the LAMP-2 gene (chromosome 12) have been reported: in exon 7 
resulting in the syndrome and with the patient requiring heart transplantation at 41years of 
age46, in intron 647, in intron 848 with additional hepatopathy, in exon 549 and in exon 4 with 
several both male and female familiy members being affected50. Another missense mutation 
in the LAMP-2 gene caused a much milder clinical picture with exercise intolerance, 
persistent HyperCKemia and hypertrophic cardiomyopathy, but no mental retardation or 
severe heart failure51.  Other genes have to be involved, suggested not only by the fact that 
the disease is always much more severe in male patients than in females, but also by marked 
phenotypic variation in unrelated patients with the same LAMP-2 gene mutation52 - in a 
family with a mutation in exon 2 of the Lamp-2 gene53, females developed isolated 
cardiomyopathy in adulthood, whereas males presented with cardiomyopathy, myopathy, 
and mental retardation before the age of 20 years. Intrafamilial variability of affected familiy 
members does occur54. Moreover, a case with quite the same clinical picture of Danon´s 
disease but normal LAMP-2 staining in the muscle biopsy has been reported55.  In mice, 
LAMP-2 deficiency increases mortality between 20 and 40 days of age56 , the surviving mice 
are fertile and have an almost normal life span. Only the additional knock-out of LAMP-1 
and -2 results in a lethal phenotype at embryonic stage57. Many tissues including liver, 
pancreas, spleen, kidney and skeletal and heart muscle accumulate autophagic vacuoles. In 
hepatocytes, the autophagic degradation of long-lived proteins is severely impaired. Cardiac 
myocytes are ultrastructurally abnormal and heart contractility is severely reduced. The 
reason for this reduced contractility is not completely understood yet; calcium handling by 
the cardiomyocytes is normal58. Finally, when cases of Danon patients with oculocutaneous 
albinism were reported in 200659, it became clear that features of Danon and Hermansky-
Pudlak syndromes may sometimes not be separable. 
6. Conclusion 
Recent years have seen a number of breakthroughs in our understanding of 
glomerulonephritis. The common theme in all of these cases is that disease entities, which 
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used to be defined simply by histomorphological criteria or clinical pictures, could be traced 
down to the underlying causative agent. In ANCA positive vasculitis, as in polyarteriitis 
nodosa, hitherto unknown roles of infective agents that give rise to the disease-defining 
immunological responses were identified: while most polyarteriitis nodosa cases are related 
to the hepatitis B virus60, fimbriated bacteria causing cross-reactions against lysosomal 
membrane proteins are involved in a majority of ANCA positive vasculitis cases. 
The story of LAMP-1 and -2 (or CD107a and b, as they have also been referred to61) 
continues. More splice variants were detected, so a whole new nomenclature was 
introduced62, the new class of LAMP-3 and the LIMP´s (lysosomal integral membrane 
proteins) entered the stage. Possible additional roles of LAMP-2 as a diagnostic marker need 
to be investigated further – conceivably it might play a role as a tumour marker as well as in 
screening of newborns for presymptomatic lysosomal storage disease: In a study LAMP-2 
plasma concentrations were increased in >66% of patients with lysosomal storage 
disorders63, and the increases coincided with increased LAMP-1 concentrations. Increased 
LAMP-1 and -2 levels have been associated with normal mast cell activation64, increased 
LAMP-2 expression in peripheral leucocytes with coronary artery disease65. There seems to 
be the possibility of a non-genetic, acquired LAMP-2 deficiency in alcoholic acute 
pancreatitis or severe endotoxemia66. Whether all these associations, or the report of Anti-
LAMP-2 ANCA´s in pyoderma gangrenosum67, or indeed the slowing down of aging 
processes by restoration of chaperone-mediated autophagy in aging cells (“Live longer with 
LAMP-2 !” 68) will gain clinical significance in the future, remains to be seen. 
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